Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

January 31, 2013

Conditions
Solid Tumors
Interventions
DRUG

ME-143

"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."

Trial Locations (2)

37203

Tennessee Oncology, PLLC, Nashville

73104

Oklahoma University Cancer Institute, Oklahoma City

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

SCRI Development Innovations, LLC

OTHER

lead

MEI Pharma, Inc.

INDUSTRY